Please assess the completion status of the following clinical trial:

Trial Title: BMS-354825 in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Is Resistant to Imatinib Mesylate

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
INCLUSION CRITERIA:~* Diagnosis of Philadelphia chromosome positive, chronic phase chronic myelogenous leukemia (CML) meeting all of the following criteria\*:~* Less than 15% blasts in peripheral blood and bone marrow~* Less than 20% basophils in peripheral blood~* Less than 30% blasts and promyelocytes in peripheral blood and bone marrow~* Platelet count at least 100,000/mm\^3 NOTE: \*Patients who previously met the criteria for accelerated phase or blast phase CML, responded to treatment, and currently meet the criteria for chronic phase CML are eligible~* Primary or acquired hematologic resistance to imatinib mesylate OR intolerance to imatinib mesylate defined as follows:~* Primary hematologic resistance is defined as failure to reach complete hematologic response (CHR) with a dose of 400 mg/day continued for at least 3 months~  * Patients with hematological progression (i.e., WBC at least 10,000/mm\^3 and rising consistently on at least 2 consecutive measurements obtained at least 14 days apart) while receiving imatinib mesylate of 400 mg/day are eligible if they have received less than 3 months of therapy~* Acquired hematologic resistance is defined as achieving a CHR, but subsequently developing a rising WBC to at least 10,000/mm\^3~  * WBC must be at least 10,000/mm\^3 and rising on at least 2 measurements obtained at least 14 days apart with at least 1 of these measurements greater than 15,000/mm\^3~* Intolerance is defined as having discontinued imatinib mesylate due to nonhematologic toxicity of any grade~  * CD4\^+ T-cell count at least 350/mm\^3~* 18 and over~* ECOG 0-1~* Life expectancy, At least 6 months.~* Hepatic~  * Bilirubin no greater than 1.5 mg/dL~ * ALT and AST no greater than 2.0 times upper limit of normal (ULN)~* Renal~  * Creatinine no greater than 1.5 times ULN~ * Potassium normal\*~ * Magnesium normal\*~ * Serum calcium or ionized calcium at least lower limit of normal NOTE: \*Patients with low levels may be repleted to be eligible~* Negative pregnancy test~* Fertile patients must use effective contraception for 1 month before, during, and 1 month after study participation~* More than 14 days since prior interferon~* More than 14 days since prior cytarabine~* More than 3 days since prior hydroxyurea~* More than 28 days since other prior investigational or antineoplastic agents~* More than 7 days since prior imatinib mesylate~* At least 5 days or 5 half-lives since prior medications that inhibit platelet function, including the following:~* Aspirin~* Dipyridamole~* Epoprostenol~* Eptifibatide~* Clopidogrel~* Cilostazol~* Abciximab~* Ticlopidine~* At least 5 days or 5 half-lives since prior anticoagulants such as warfarin or heparin/low molecular weight heparin (e.g., danaparoid, dalteparin, tinzaparin, enoxaparin)~* At least 5 days or 5 half-lives since prior drugs accepted to have a risk of causing torsades de pointes, including the following:~* Class IA antiarrhythmic agents (e.g., quinidine, procainamide, or disopyramide)~* Class III antiarrhythmic agents (e.g., amiodarone, sotalol, ibutilide, or dofetilide)~* Macrolide antibiotics (e.g., erythromycin or clarithromycin)~* Antipsychotics (e.g., chlorpromazine, haloperidol, thioridazine, or pimozide)~* Tricyclic antidepressants~* Cisapride~* Bepridil~* Inapsine~* Methadone~* Arsenic~* Concurrent anagrelide for thrombocytosis due to CML allowed~Exclusion Criteria:~* extramedullary involvement (other than liver or spleen)~* significant bleeding disorder unrelated to CML~* acquired bleeding disorder within the past year (e.g., acquired antifactor VIII antibodies)~* congenital bleeding disorders (e.g., von Willebrand disease)~* uncontrolled or significant cardiovascular disease~* uncontrolled angina within the past 6 months~* congestive heart failure within the past 6 months~* myocardial infarction within the past 12 months~* history of clinically significant ventricular arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, or torsades de pointes)~* history of second or third degree heart block (may be eligible if patient has a pacemaker)~* diagnosed or suspected congenital long QT syndrome~* prolonged QTc interval on pre-entry EKG (i.e., greater than 450 msec)~* heart rate less than 50/minute on pre-entry EKG~* uncontrolled hypertension~* vasculitis~* pregnant or nursing~* gastrointestinal tract bleeding within the past 6 months~* connective tissue disorders~* other serious uncontrolled medical disorder or active infection that would impair the ability to receive study therapy~* dementia or altered mental status that would preclude giving informed consent~* evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, EKG, or clinical laboratory determinations unrelated to CML~* prisoners or patients who are compulsorily detained (e.g., involuntary incarceration for treatment of either a psychiatric or physical \[e.g., infectious disease\] illness)~* concurrent drugs accepted to have a risk of causing torsades de pointes~* other concurrent treatment for CML~* concurrent dolasetron or droperidol~* concurrent anticoagulants~* concurrent medications that inhibit platelet function

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete